Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

BACKGROUND: Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis. OBJECTIVES: To evaluate the long‐term efficacy and safety of tildrakizumab treatment for patients with moderate‐to‐severe psoriasis for up to 148 weeks. METHODS: Pooled...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064936/
https://www.ncbi.nlm.nih.gov/pubmed/31218661
http://dx.doi.org/10.1111/bjd.18232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064936/
https://www.ncbi.nlm.nih.gov/pubmed/31218661
http://dx.doi.org/10.1111/bjd.18232

Ejemplares similares